With over 40% of new drug substances exhibiting poor aqueous solubility, a major task has been to explore potential alternative procedures for overcoming this undesirable and problematic characteristic.
Poor solubility can greatly compromise the bioavailability of a drug, and thereby detract from optimising the clinical efficacy of these promising candidates. With supercritical fluid processing, micron- and sub-micron sized, particles with morphologies giving high surface areas can be readily produced. These provide the opportunity to maximise particle dissolution rate, and optimise dosage forms for these previously challenging molecules.
The Crystec team also have the capability to engineer composite particles, potentially incorporating enhancer molecules which can help to overcome notoriously difficult obstacles such as the blood-brain barrier, or to stabilise amorphous forms.
CrystecPharma's intellectual property strategy is to protect products, maintaining its technology platform and scale-up expertise as a trade secret.
We are keen to work with companies developing small and large molecule therapeutics, facing challenges of poor bioavailability.
Miss Catherine Hunter
Business Development Manager
CrystecPharma applies the latest supercritical fluid (SCF) technologies to improve the design and performance of medicinesView profile
Clients in focus...